Profit Margin Pressure Forces Cipla To Cut Back On Its Claim To Fame - Antiretroviral Drugs
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In a seemingly unexpected development, Indian drug maker Cipla has decided to gradually exit from the tender-based antiretrovirals business - a move that it hopes will help in improving profit margins though volumes may dip in the short term
You may also be interested in...
Gilead Fights For Viread Patent And Royalties In India
Gilead Sciences is challenging a decision in India refusing patent protection for its worldwide HIV blockbuster drug Viread (tenofovir)
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).